Overview

A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

Status:
Completed

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

Summary

Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients suffering from nasal symptoms alone. Fluticasone furoate (FF) acts against both nasal and ocular symptoms. The purpose of this study was to evaluate the differences in symptom control (both perceptually and objectively) and resource use for patients with current seasonal AR.

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

Adelphi Real World

Treatments:

Fluticasone
Mometasone Furoate
Xhance